Valneva submitted label extension applications to the U.S. Food and Drug Administration (FDA)5, the European Medicines Agency (EMA) and Health Canada6 to potentially extend the use of IXCHIQ® to ...

Legend has it he once fought off a bear single-handedly. I'm serious. Robert Alexander / Getty Images 8.This is Maud Wagner, who is widely believed to be the first female professional tattoo ...

Jackson Mahomes is pictured with his mother, Randi, on Feb. 8. Getty Images “It’s always cool to be able to play in front of a sitting president,” Mahomes told reporters this week in New ...

Complemented by international loans, the exhibition showcases, for the first time, the museum's own collection of American images, which it has been busy expanding since 2007. America and ...

The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years and older, but Bavarian Nordic’s Vimkunya is the first chikungunya vaccine ...

Since placing a few digital picture frames around my house, though, I’ve been able to grace my home with pictures of my sister and her kids who live states away, plus photos she and my mom ...

Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, commented, “This latest approval is a further recognition of IXCHIQ ® ’s strong product profile and the medical need for a ...

Space can be a wondrous place, and we've got the pictures to prove it! Take a look at our favorite space pictures here, and if you're wondering what happened to today in space history don't miss ...

Valneva has acknowledged that the initial rollout of Ixchiq has been slow, but it expects sales to ramp up, potentially fuelled by label extensions in children, adolescents, and pregnant women ...

The French pharma company – best known for its COVID-19 jab and recent approval for the world's first chikungunya vaccine Ixchiq – is paying €10 million upfront for a stake in LimmaTech's ...

During the open-label extension phase of the study ... The agency approved the company's chikungunya vaccine, Ixchiq, for use in people 18 years of age and older. Late-stage trial data show ...